Vyzulta™ (latanoprostene bunod) – New drug approval
November 2, 2017 – Bausch and Lomb/Valeant and Nicox announced the FDA approval of Vyzulta (latanoprostene bunod) for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Download PDF
